Breast Cancer

The FDA placed a partial clinical hold on a phase 1 trial evaluating YL202 in select patients with advanced non–small cell lung cancer or breast cancer.

Medical experts delve into the challenges of brain metastases in HER2-positive breast cancer, exploring local therapies for targeting central nervous system metastases and emphasizing the crucial role of multidisciplinary tumor boards, collaboration with colleagues, and referrals to specialized providers in optimizing patient outcomes.

Paolo Tarantino, MD, and Yan Leyfman, MD, discuss ongoing investigations into the treatment of HR+ breast cancer presented at the 2024 ASCO Annual Meeting.

Key opinion leaders revisit the HER2CLIMB trial, providing an in-depth analysis of the latest updates and their implications for the management of HER2-positive metastatic breast cancer.

Kevin Kalinsky, MD, MS, discusses the utility of the postMONARCH trial regimen in hormone receptor–positive/HER2-negative advanced breast cancer.

Arya Mariam Roy, MBBS, discusses the role of polygenic scores in predicting the risk of recurrence and survival outcomes in breast cancer.

Decreases in variant allele frequency in ctDNA were linked to improved CBR with imlunestrant in estrogen receptor–positive, HER2-negative breast cancer

Brittany Bychkovsky, MD, MSc, discusses the role of genetic testing in breast cancer care and explores approaches to improving the testing process.

Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.

Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.

MammaPrint high 2 HR-positive/HER2-negative early-stage breast cancer exhibited a heightened immune active state.

VK Gadi, MD, PhD, discusses primary results from the phase 3 DESTINY-Breast06 trial of trastuzumab deruxtecan in HR-positive, HER2-low breast cancer.

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Brittany L. Bychkovsky, MD, MSc, and Lydia Pace, MD, MPH, explain approaches to breast cancer screening and considerations with the final USPSTF screening recommendations.

Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.

Key opinion leaders explore various therapeutic options for later-line treatment of HER2-positive metastatic breast cancer, emphasizing the significance of the HER2CLIMB and CLEOPATRA trials, while also drawing comparisons to real-world data to inform clinical decision-making.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.

Pembrolizumab plus sacituzumab govitecan numerically improved PFS vs the ADC alone in HR-positive, HER2-negative metastatic breast cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

Inavolisib plus palbociclib and fulvestrant reduced the risk of progression or death in HR+/HER2– PIK3CA-mutated advanced or metastatic breast cancer.

Anthracycline/taxane/cyclophosphamide was linked to improved RFS in MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative breast cancer.